{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-22-000070","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.118427+00:00","generated_at":"2026-06-22T04:16:53.714994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcutis Q3 net loss $107.7M ($1.89/share); ZORYVE launch generates $0.7M revenue","bullets":["Net product revenue of $0.7M from ZORYVE launch; about half from wholesaler inventory build.","Net loss $107.7M ($1.89 per share) vs $57.0M ($1.14) YoY; Ducentis acquisition added $0.51 per share.","R&D expenses $69.7M (incl. $30M Ducentis upfront); SG&A $35.5M on launch costs.","Cash, equivalents, and marketable securities $478.2M; $162M from Aug 2022 public offering and $125M debt draw.","Positive topline Phase 3 data for roflumilast foam in scalp/body psoriasis; enrollment completed in atopic dermatitis trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-22-000070","json":"https://secwatch.observer/filing/0001787306-22-000070.json","markdown":"https://secwatch.observer/filing/0001787306-22-000070.md","text":"https://secwatch.observer/filing/0001787306-22-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/0001787306-22-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/arqt-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:16:53.714994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3f3ada46ec7c04f7605af09c31670cefdde6312","claim":"Arcutis Biotherapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730622000070/0001787306-22-000070-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}